WallStSmart
PSTV

Plus Therapeutics Inc

NASDAQ: PSTV · HEALTHCARE · BIOTECHNOLOGY

$5.60
-5.88% today

Updated 2026-04-29

Market cap
$40.83M
P/E ratio
P/S ratio
7.83x
EPS (TTM)
$-7.25
Dividend yield
52W range
$3 – $24
Volume
3.6M

Plus Therapeutics Inc (PSTV) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+47.9%
Last 4 quarters
Revenue YoY growth
-3.2%
Most recent quarter
EPS YoY growth
+91.6%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-5.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-11.5%
2026-03-13
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-13$-0.04+95.5%$0.29$0.26-11.5%
2025-10-30$-0.04+94.3%$0.54$0.54+0.3%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.92$-0.04+95.5%$1.37M-3.2%
2025-09-30$-0.70$-0.04+94.3%$1.40M-4.1%
2025-06-30$-0.13$-0.01+95.0%$1.39M+8.7%
2025-03-31$-0.29$-0.57-93.3%$1.06M-36.9%
2024-12-31$-0.50$-0.49+1.3%$1.41M+7.5%
2024-09-30$-0.56$-0.37+33.9%$1.46M+17.4%
2024-06-30$-0.53$-0.56-5.7%$1.28M-31.0%
2024-03-31$-1.09$-0.75+31.2%$1.68M+231.4%
2023-12-31$-1.07$-0.84+21.5%$1.31M
2023-09-30$-1.12$-1.00+10.7%$1.24M
2023-06-30$-1.91$-0.59+69.1%$1.85M
2023-03-31$-0.13$-0.14-7.7%$506000.00

Frequently asked questions

Has Plus Therapeutics Inc beaten earnings estimates?
Plus Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +47.9% over the last 4 quarters.
How does PSTV stock react to earnings?
PSTV stock has moved an average of -5.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Plus Therapeutics Inc's revenue growth rate?
Plus Therapeutics Inc reported year-over-year revenue growth of -3.2% in its most recent quarter, with EPS growing +91.6% year-over-year.